Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718534 | 0.91 | HDAC1 (0.56) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL719842 | 0.83 | HDAC1 (0.81) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL721440 | 0.82 | HDAC1 (0.65) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL13748129 | 0.82 | HDAC1 (0.65) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL719288 | 0.82 | HDAC1 (0.65) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL720122 | 0.81 | HDAC1 (0.61) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL14930220 | 0.80 | MAPT (0.52) | ALDH1A1MAPT | |
| SCHEMBL10436144 | 0.80 | CYP1A2 (0.49) | ALDH1A1 | |
| SCHEMBL6635270 | 0.80 | RAD52 (0.51) | ALDH1A1MAPT | |
| SCHEMBL718921 | 0.79 | HDAC1 (0.61) | HDAC1HDAC8HDAC6HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381196-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | claimed |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-07-16 | — | — | US | claimed |
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | claimed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | claimed |
| US-9381196-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381196-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-07-16 | — | — | US | disclosed |
| US-8987468-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987468-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | HDAC1 11/4885HDAC8 8/4885HDAC6 5/4885 |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | HDAC1 11/4885HDAC8 8/4885HDAC6 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.